A randomized, double-blind, placebo-controlled, phase 3 study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse

Journal of Clinical Oncology

Volumn 34, Issue 19, 2016, Pages 2271-2278

  Vergote, Ignace ^a   Armstrong, Deborah ^b   Scambia, Giovanni ^c   Teneriello, Michael ^d   Sehouli, Jalid ^e   Schweizer, Charles ^f   Weil, Susan C ^g   Bamias, Aristotelis ^h   Fujiwara, Keiichi ^g   Ochiai, Kazunori ^h   Poole, Christopher ⁱ   Gorbunova, Vera ^j   Wang, Wenquan ^f   O'Shannessy, Daniel ^f   Herzog, Thomas J ^k  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d US Oncology ^*  (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f ALEXANDRA HOSPITAL   (Greece)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

^j Russian Oncology Center   (Russian Federation)

^k UNIVERSITY OF CINCINNATI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; FARLETUZUMAB; PACLITAXEL; PLACEBO; PLATINUM; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; MONOCLONAL ANTIBODY; TAXANE; TAXOID;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERIPHERAL SENSORY NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; BLOOD; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED-RING COMPOUNDS; CA-125 ANTIGEN; CARBOPLATIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TAXOIDS;

EID: 84976430950     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.2596     Document Type: Article

References (17)

1. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France. 2013
2. O'Shannessy DJ, Somers EB, Smale R, et al: Expression of folate receptor-a (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol 32:258-268, 2013 A
3. Weitman SD, Lark RH, Coney LR, et al: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52: 3396-3401, 1992
4. Toffoli G, Cernigoi C, Russo A, et al: Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193-198, 1997
5. Chen Y-L, Chang M-C, Huang C-Y, et al: Serous ovarian carcinoma patients with high alphafolate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 6:360-369, 2012
6. Ebel W, Routhier EL, Foley B, et al: Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7:6-13, 2007
7. Lin J, Spidel JL, Maddage CJ, et al: The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther 14:1032-1038, 2013
8. Armstrong DK, White AJ, Weil SC, et al: Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 129:452-458, 2013
9. van der Burg ME, Lammes FB, Verweij J: The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1:301-302, 1990
10. Pignata S, Cannella L, Leopardo D, et al: Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol 22, 2011 (suppl 8):viii40-viii44
11. Markman M, Liu PY, Rothenberg ML, et al: Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 24:1454-1458, 2006
12. Mutch DG, Orlando M, Goss T, et al: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25: 2811-2818, 2007
13. Patankar MS, Jing Y, Morrison JC, et al: Potent suppression of natural killer cell response. Gynecol Oncol 99:704-713, 2005
14. Felder M, Kapur A, Gonzalez-Bosquet J, et al: MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress. Mol Cancer 13:129, 2014
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. E9 Statistical Principles for Clinical Trials: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); 1998
17. Stuart GC, Kitchener H, Bacon M, et al: 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21:750-755, 2011